Related Experiment Video
Updated: Feb 2, 2026
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
[Diagnosis and Treatment of Familial Hypercholesterolemia]
Manuela Schöb1, Pascal Müller2, Yannick Gerth3
11 Klinik für Endokrinologie, Diabetologie, Osteologie und Stoffwechselkrankheiten, Kantonsspital St. Gallen.
Insights
Familial hypercholesterolemia (FH) causes high LDL cholesterol, leading to early heart disease. Early diagnosis and family screening are crucial for effective treatment and preventing cardiovascular events.
Area of Science:
- Cardiology
- Genetics
- Metabolic Disorders
Background:
- Familial hypercholesterolemia (FH) results from genetic mutations affecting LDL cholesterol metabolism.
- It leads to significantly elevated LDL cholesterol, premature atherosclerosis, and cholesterol deposits.
- Polygenic forms of FH share similar clinical presentations.
Purpose of the Study:
- To highlight the underdiagnosis and undertreatment of FH.
- To emphasize the importance of early diagnosis and cascade screening in families.
- To discuss effective lipid-lowering strategies for FH patients.
Main Methods:
- Review of existing literature on FH diagnosis and treatment.
- Analysis of cardiovascular risk factors associated with FH.
- Evaluation of current treatment guidelines and emerging therapies.
Main Results:
- Statins are effective for primary prevention in FH, yet less than 10% are diagnosed in Switzerland.
- Untreated FH frequently manifests as clinical cardiovascular events.
- Combination therapy (statins, ezetimibe, PCSK9 inhibitors) effectively lowers LDL cholesterol.
Conclusions:
- Accurate diagnosis of index patients and cascade screening are essential to identify and treat FH before complications arise.
- Prompt and effective lipid-lowering treatment is vital for managing FH.
- Combination therapy offers successful LDL cholesterol reduction in FH patients, particularly those with existing cardiovascular disease.
Abstract:
Diagnosis and Treatment of Familial Hypercholesterolemia Abstract. Familial hypercholesterolemia secondary to heterozygous mutations in the LDL receptor, Apolipoprotein B or PCSK9 gene is characterized by 2- to 3-fold elevated LDL cholesterol levels, premature atherosclerosis and extravascular cholesterol deposits (tendon xanthomata, corneal arcus). The same phenotype may occur if a person carries several LDL cholesterol rising polymorphisms (polygenic FH). Primary prevention with statins has been shown to dramatically reduce the cardiovascular burden in patients with the disease. However, it is estimated that less than 10 % of affected subjects in Switzerland have received the diagnosis, and undertreatment is frequent. Thus, clinical cardiovascular events are still the first manifestation of the disease in many cases. A correct diagnosis in index patients and cascade screening of families are mandatory to identify and treat patients before they suffer the sequelae of untreated severe hypercholesterolemia. In patients with clinical cardiovascular disease combination lipid lowering treatment with potent statins, ezetimibe and the newly available PCSK9 inhibitors will successfully lower LDL cholesterol to normal or even target levels.
Related Concept Videos
02:47Protein Families
02:47Protein Families
01:57Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
01:57Gene Families
01:30Family Therapy
Strategic Family Therapy
Strategic family therapy emphasizes resolving communication barriers and improving problem-solving abilities...
01:18Sources of Self-Esteem I: Family Experience